We wouldn’t dare miss the annual “Gospodarcze Otwarcie Roku” (Business Opening of the Year) conference on 21 February 2018. The meeting allows Polish entrepreneurs and financial experts to share their perspectives on forecasts, threats and opportunities for our country, Europe and the world. The topics discussed during this edition included the financing opportunities and investment prospects for the most innovative enterprises.
At the conference, we showcased our solutions for producing stem cell pharmaceuticals for veterinary use, including a biopharmaceutical suspension of mesenchymal stem cells (MSCs) intended for use in treating degenerative joint diseases in dogs.
Find out more about the event at: http://kig.pl/strona-glowna/aktualnosci/szczegoly/8735/
Puls Biznesu about our plans: Bioceltix announces that it will soon debut on NewConnect – the company has recently completed the pre-IPO round. So far, the company has obtained a total of approx. PLN 20 million in financing for the development of a still innovative method of treating pets ...
ArticleForbes about Polish start-ups in the coronavirus crisis: “The year 2020 was a big challenge for companies, individual sectors of the economy and probably all of us. In the coming weeks and months of 2021 it will be similar. The condition of start-ups is no exception here. it is easier and ...
ArticleAccording to the „Investors’ Zone”, an interesting year is being prepared on the stock exchange: “This year, an exceptionally large group of companies is choosing NewConnect. As many as 63 companies declared their willingness to enter the alternative market, and several more in the ...
ArticleGazeta Wrocławska wrote about us: “Bioceltix is working on innovative biological medicines used in the treatment of common autoimmune and inflammatory diseases in companion animals. The company from Wrocław has something to fight for. This is indicated by the numbers on the global drug ...
ArticleWe create at Bioceltix veterinary biological medicines, and in 2020 we announced plans for a stock exchange debut and we obtained a permit from the Main Pharmaceutical Inspector to manufacture veterinary biological drugs. Despite the pandemic, we continue our projects without downtime. You can ...
Article
